CN Patent

CN103889221A — 抗真菌剂及其应用

Assigned to Nap Pharmaceutical Group Co ltd · Expires 2014-06-25 · 12y expired

What this patent protects

本发明的特征为棘白菌素类化合物，所述化合物可用于真菌感染的治疗。所述棘白菌素类化合物经修饰，以使它们可显示出(i)对抗一种或多种真菌种类或属的活性；(ii)增加的水溶性和/或两亲性；(iii)具有增加的治疗指数；(iv)局部给药的适应性；(v)静脉内给药的适应性；(vi)具有增加的分布的体积；和/或(vii)具有增加的清除半衰期。

USPTO Abstract

本发明的特征为棘白菌素类化合物，所述化合物可用于真菌感染的治疗。所述棘白菌素类化合物经修饰，以使它们可显示出(i)对抗一种或多种真菌种类或属的活性；(ii)增加的水溶性和/或两亲性；(iii)具有增加的治疗指数；(iv)局部给药的适应性；(v)静脉内给药的适应性；(vi)具有增加的分布的体积；和/或(vii)具有增加的清除半衰期。

Drugs covered by this patent

rezafungin-acetate (REZAFUNGIN ACETATE)

Patent Metadata

Patent number: CN103889221A
Jurisdiction: CN
Classification: —
Expires: 2014-06-25
Drug substance claim: No
Drug product claim: No
Assignee: Nap Pharmaceutical Group Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.